Anti-GD1a GangliosideclGD1a-1(Az. Free)

Not available outside of the UK & Ireland.

Application

Anti-GD1a Ganglioside Antibody, clone GD1a-1 (Azide Free) is an antibody against GD1a Ganglioside for use in Immunohistochemistry (Paraffin) and Enzyme Immunoassay (ELISA).

Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected GD1a Ganglioside in human prostate tissue.
ELISA Analysis: Target specificity of a representative lot was determined by ELISA analysis (Gong, Y., et al. (2002). Brain. 125(Pt 11):2491-2506).
Immunohistochemistry Analysis: A representative lot detected GD1a immunoreactivity in fresh-frozenmid-sagittal brain sections from wild-type and St3gal2/3-double-null mice (Sturgill, E.R., et al. (2012). Glycobiology.22(10):1289-1301).
Immunohistochemistry Analysis: A representative lot detected GD1a immunoreactivity in various fish brain regions using free-floating sections (Viljetić, B., et al. (2012). Biochim Biophys Acta. 1820(9):1437-1443).
Immunohistochemistry Analysis: A representative lot detected GD1a in fresh-frozen human and rat brain sections by both fluorescent and non-fluorescent immunohistochemistry (Gong, Y., et al. (2002). Brain. 125(Pt 11):2491-2506).
Immuno-overlay Assay: A representative lot detected bovine brain GD1a, as well as GD1a in human ventral and dorsal root gangliosides extracts (Gong, Y., et al. (2002). Brain. 125(Pt 11):2491-2506).

Research CategoryNeuroscience

Research Sub CategoryDevelopmental Neuroscience

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Gangliosides are sialic acid-containing oligoglycosylceramides. The German scientist Ernst Klenk used the term ganglioside in 1942 to refer to lipids isolated from ganglions. Gangliosides are grouped based on the number of sialic acid residues per molecule, GM gangliosides contain one sialic acid residue, GD gangliosides contain two, GT contain three, GQ contain four sialic acid residues. Glycolipids constitute >80% of mammalian brain glycans, with gangliosides being the major glycans in nerve cells. Among the hundreds of ganglioside structures, GM1a, GD1a, GD1b and GT1b comprise up to 97% of gangliosides in the human brain. These four gangliosides share the same neutral tetrasaccharide core (Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1′Cer), but differ from each other by their sialic acid residue(s). GM1a and GD1b contain one or two sialic acids on the internal galactose, respectively, and no sialic acid on the terminal galactose. The St3gal2 and St3gal3 gene products (ST3Gal-II and ST3Gal-III sialyltransferase, respectively) are largely responsible for ganglioside terminal A2-3 sialylation of GM1a and GD1b to produce GD1a and GT1b in the brain. Brain GD1a and GT1b in St3gal2-null mice is about half the level in wild-type mice, while GD1a and GT1b level in St3gal2/3-double-null mice is less than 5% of the level in wild-type mice. St3gal2/3-double-null mice are half the weight of wild-type mice at weaning and display early hindlimb dysreflexia.

Immunogen

KLH-conjugated GD1a ganglioside.

Linkage

Replaces: MAB5606

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Protein G Purified

Purified mouse monoclonal IgG1κ antibody in buffer containing PBS with no azide

Format: Purified

Quality

Evaluated by Immunohistochemistry in human heart tissue.

Immunohistochemistry Analysis: A 1:50 dilution of this antibody detected GD1a Ganglioside in human heart tissue.

Specificity

GD1a ganglioside. The antibody shows approximately 10% reactivity to GalNAc-GD1a and GT1aα. Preferentially binds to motor myelinated fibers in cross-sections of ventral roots and sciatic nerves.

Storage and Stability

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.